Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Constipation | Research

Efficacy of washed microbiota transplantation for therapeutic targets of refractory functional constipation and the influencing factors: a single-center, retrospective, 24-week follow-up study

Authors: Liquan Wu, Qingfen Yuan, Lihao Wu, Harry Hua-Xiang Xia, Muxiao Zhong, Tao Liu, Xiaoyan Ye, Danping Luo, Jiating Xu, Wenrui Xie, Xingxiang He, Jieyi Cai

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

The efficacy of washed microbiota transplantation (WMT) in terms of refractory functional constipation (FC)-related therapeutic targets and influencing factors have not been elucidated. This study aimed to assess the efficacy and influencing factors of WMT in treating refractory FC-related therapeutic targets.

Methods

The clinical data of patients diagnosed with refractory FC and received with WMT were retrospectively collected. The therapeutic targets included straining, hard stools, incomplete evacuation, a sense of anorectal obstruction, manual maneuvers, and decreased stool frequency. Each target was recorded as 1 (yes) or 0 (no). All patients were followed up for approximately 24 weeks from the end of the first course of WMT. The primary outcomes were the improvement rates for the individual therapeutic targets and the overall response in respect of the therapeutic targets decreased by 2 at weeks 4, 8, and 24. The secondary outcomes were the clinical remission rate (i.e., the proportion of patients with an average of 3 or more spontaneous complete bowel movements per week), clinical improvement rate (i.e., the proportion of patients with an average increase of 1 or more SCBMs/week or patients with remission), stool frequency, Wexner constipation score, Bristol Stool Form Scale (BSFS) score, and adverse events. The factors influencing the efficacy were also analyzed.

Results

Overall, 63 patients with 112 WMT courses were enrolled. The improvement rates at weeks 8 and 24 were 45.6% and 35.0%, 42.9% and 38.6%, 45.0% and 35.7%, 55.6% and 44.4%, and 60.9% and 50.0%, respectively, for straining, hard stools, incomplete evacuation, a sense of anorectal obstruction, and decreased stool frequency. The overall response rates were 49.2%, 50.8%, and 42.9%, respectively, at weeks 4, 8, and 24. The rates of clinical remission and clinical improvement were 54.0% and 68.3%, respectively, at weeks 4. The stool frequency, BSFS score, and Wexner constipation score tended to improve post-WMT. Only 22 mild adverse events were observed during the 112 WMT courses and the follow-up. The number of WMT courses was identified to be the independent factor influencing the efficacy.

Conclusions

WMT is efficacious in improving refractory FC-related therapeutic targets. The effectiveness of WMT in the management of FC is enhanced with the administration of multiple courses.
Literature
1.
go back to reference Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, results of Rome Foundation Global Study. Gastroenterology. 2021;160:99–114e3.PubMed Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, results of Rome Foundation Global Study. Gastroenterology. 2021;160:99–114e3.PubMed
2.
go back to reference Black CJ, Drossman DA, Talley NJ, Ruddy J, Ford AC. Functional gastrointestinal disorders: advances in understanding and management. Lancet. 2020;396:1664–74.PubMed Black CJ, Drossman DA, Talley NJ, Ruddy J, Ford AC. Functional gastrointestinal disorders: advances in understanding and management. Lancet. 2020;396:1664–74.PubMed
3.
go back to reference Sharma A, Rao SSC, Kearns K, Orleck KD, Waldman SA. Review article: diagnosis, management and patient perspectives of the spectrum of constipation disorders. Aliment Pharmacol Ther. 2021;53:1250–67.PubMedCentralPubMed Sharma A, Rao SSC, Kearns K, Orleck KD, Waldman SA. Review article: diagnosis, management and patient perspectives of the spectrum of constipation disorders. Aliment Pharmacol Ther. 2021;53:1250–67.PubMedCentralPubMed
4.
go back to reference Bharucha AE, Lacy BE. Mechanisms, evaluation, and management of chronic constipation. Gastroenterology. 2020;158:1232–49e3.PubMed Bharucha AE, Lacy BE. Mechanisms, evaluation, and management of chronic constipation. Gastroenterology. 2020;158:1232–49e3.PubMed
5.
go back to reference Ohkusa T, Koido S, Nishikawa Y, Sato N. Gut microbiota and chronic constipation: a review and update. Front Med (Lausanne). 2019;6:19.PubMed Ohkusa T, Koido S, Nishikawa Y, Sato N. Gut microbiota and chronic constipation: a review and update. Front Med (Lausanne). 2019;6:19.PubMed
6.
go back to reference Zhang X, Li N, Chen Q, Qin H. Fecal microbiota transplantation modulates the Gut Flora favoring patients with functional constipation. Front Microbiol. 2021;12:700718.PubMedCentralPubMed Zhang X, Li N, Chen Q, Qin H. Fecal microbiota transplantation modulates the Gut Flora favoring patients with functional constipation. Front Microbiol. 2021;12:700718.PubMedCentralPubMed
7.
go back to reference Dimidi E, Christodoulides S, Scott SM, Whelan K. Mechanisms of action of Probiotics and the gastrointestinal microbiota on gut motility and constipation. Adv Nutr. 2017;8:484–94.PubMedCentralPubMed Dimidi E, Christodoulides S, Scott SM, Whelan K. Mechanisms of action of Probiotics and the gastrointestinal microbiota on gut motility and constipation. Adv Nutr. 2017;8:484–94.PubMedCentralPubMed
8.
go back to reference Tian Y, Zuo L, Guo Q, Li J, Hu Z, Zhao K, et al. Potential role of fecal microbiota in patients with constipation. Th Adv Gastroenterol. 2020;13:1756284820968423. Tian Y, Zuo L, Guo Q, Li J, Hu Z, Zhao K, et al. Potential role of fecal microbiota in patients with constipation. Th Adv Gastroenterol. 2020;13:1756284820968423.
9.
go back to reference Huang L, Zhu Q, Qu X, Qin H. Microbial treatment in chronic constipation. Sci China Life Sci. 2018;61:744–52.PubMed Huang L, Zhu Q, Qu X, Qin H. Microbial treatment in chronic constipation. Sci China Life Sci. 2018;61:744–52.PubMed
10.
go back to reference Zhang T, Lu G, Zhao Z, Liu Y, Shen Q, Li P, et al. Washed microbiota transplantation vs. manual fecal microbiota transplantation: clinical findings, animal studies and in vitro screening. Protein Cell. 2020;11:251–66.PubMedCentralPubMed Zhang T, Lu G, Zhao Z, Liu Y, Shen Q, Li P, et al. Washed microbiota transplantation vs. manual fecal microbiota transplantation: clinical findings, animal studies and in vitro screening. Protein Cell. 2020;11:251–66.PubMedCentralPubMed
11.
go back to reference Zheng YM, Chen XY, Cai JY, Yuan Y, Xie WR, Xu JT, et al. Washed microbiota transplantation reduces proton pump inhibitor dependency in nonerosive reflux disease. World J Gastroenterol. 2021;27:513–22.PubMedCentralPubMed Zheng YM, Chen XY, Cai JY, Yuan Y, Xie WR, Xu JT, et al. Washed microbiota transplantation reduces proton pump inhibitor dependency in nonerosive reflux disease. World J Gastroenterol. 2021;27:513–22.PubMedCentralPubMed
12.
go back to reference Ye ZN, Xia HH, Zhang R, Li L, Wu LH, Liu XJ, et al. The efficacy of washed microbiota transplantation on Helicobacter pylori Eradication: a pilot study. Gastroenterol Res Pract. 2020;2020:8825189.PubMedCentralPubMed Ye ZN, Xia HH, Zhang R, Li L, Wu LH, Liu XJ, et al. The efficacy of washed microbiota transplantation on Helicobacter pylori Eradication: a pilot study. Gastroenterol Res Pract. 2020;2020:8825189.PubMedCentralPubMed
13.
go back to reference Zheng YM, He XX, Xia HH, Yuan Y, Xie WR, Cai JY, et al. Multi-donor multi-course faecal microbiota transplantation relieves the symptoms of chronic hemorrhagic radiation proctitis: a case report. Med (Baltim). 2020;99:e22298. Zheng YM, He XX, Xia HH, Yuan Y, Xie WR, Cai JY, et al. Multi-donor multi-course faecal microbiota transplantation relieves the symptoms of chronic hemorrhagic radiation proctitis: a case report. Med (Baltim). 2020;99:e22298.
14.
go back to reference Xie WR, Yang XY, Deng ZH, Zheng YM, Zhang R, Wu LH, et al. Effects of washed microbiota transplantation on serum uric acid levels, symptoms, and intestinal barrier function in patients with Acute and recurrent gout: a pilot study. Dig Dis. 2022;40:684–90. Xie WR, Yang XY, Deng ZH, Zheng YM, Zhang R, Wu LH, et al. Effects of washed microbiota transplantation on serum uric acid levels, symptoms, and intestinal barrier function in patients with Acute and recurrent gout: a pilot study. Dig Dis. 2022;40:684–90.
15.
go back to reference Zhong HJ, Zeng HL, Cai YL, Zhuang YP, Liou YL, Wu Q, et al. Washed microbiota transplantation lowers blood pressure in patients with hypertension. Front Cell Infect Microbiol. 2021;11:679624.PubMedCentralPubMed Zhong HJ, Zeng HL, Cai YL, Zhuang YP, Liou YL, Wu Q, et al. Washed microbiota transplantation lowers blood pressure in patients with hypertension. Front Cell Infect Microbiol. 2021;11:679624.PubMedCentralPubMed
16.
go back to reference Liang F, Lu X, Deng Z, Zhong HJ, Zhang W, Li Q, et al. Effect of washed microbiota transplantation on patients with Dyslipidemia in South China. Front Endocrinol (Lausanne). 2022;13:827107.PubMed Liang F, Lu X, Deng Z, Zhong HJ, Zhang W, Li Q, et al. Effect of washed microbiota transplantation on patients with Dyslipidemia in South China. Front Endocrinol (Lausanne). 2022;13:827107.PubMed
17.
go back to reference Pan ZY, Zhong HJ, Huang DN, Wu LH, He XX. Beneficial Effects of repeated washed microbiota transplantation in Children with Autism. Front Pediatr. 2022;10:928785.PubMedCentralPubMed Pan ZY, Zhong HJ, Huang DN, Wu LH, He XX. Beneficial Effects of repeated washed microbiota transplantation in Children with Autism. Front Pediatr. 2022;10:928785.PubMedCentralPubMed
18.
go back to reference Zhang X, Tian H, Gu L, Nie Y, Ding C, Ge X, et al. Long-term follow-up of the effects of fecal microbiota transplantation in combination with soluble dietary fiber as a therapeutic regimen in slow transit constipation. Sci China Life Sci. 2018;61:779–86. Zhang X, Tian H, Gu L, Nie Y, Ding C, Ge X, et al. Long-term follow-up of the effects of fecal microbiota transplantation in combination with soluble dietary fiber as a therapeutic regimen in slow transit constipation. Sci China Life Sci. 2018;61:779–86.
19.
go back to reference Ding C, Fan W, Gu L, Tian H, Ge X, Gong J, et al. Outcomes and prognostic factors of fecal microbiota transplantation in patients with slow transit constipation: results from a prospective study with long-term follow-up. Gastroenterol Rep (Oxf). 2018;6:101–7.PubMed Ding C, Fan W, Gu L, Tian H, Ge X, Gong J, et al. Outcomes and prognostic factors of fecal microbiota transplantation in patients with slow transit constipation: results from a prospective study with long-term follow-up. Gastroenterol Rep (Oxf). 2018;6:101–7.PubMed
20.
go back to reference Tian H, Ge X, Nie Y, Yang L, Ding C, McFarland LV, et al. Fecal microbiota transplantation in patients with slow-transit constipation: a randomized, clinical trial. PLoS ONE. 2017;12:e0171308.PubMedCentralPubMed Tian H, Ge X, Nie Y, Yang L, Ding C, McFarland LV, et al. Fecal microbiota transplantation in patients with slow-transit constipation: a randomized, clinical trial. PLoS ONE. 2017;12:e0171308.PubMedCentralPubMed
21.
go back to reference Tian H, Ding C, Gong J, Ge X, McFarland LV, Gu L, et al. Treatment of slow transit constipation with fecal microbiota transplantation: a pilot study. J Clin Gastroenterol. 2016;50:865–70.PubMed Tian H, Ding C, Gong J, Ge X, McFarland LV, Gu L, et al. Treatment of slow transit constipation with fecal microbiota transplantation: a pilot study. J Clin Gastroenterol. 2016;50:865–70.PubMed
22.
go back to reference Xie L, Xu C, Fan Y, Li Y, Wang Y, Zhang X, et al. Effect of fecal microbiota transplantation in patients with slow transit constipation and the relative mechanisms based on the protein digestion and absorption pathway. J Transl Med. 2021;19:490.PubMedCentralPubMed Xie L, Xu C, Fan Y, Li Y, Wang Y, Zhang X, et al. Effect of fecal microbiota transplantation in patients with slow transit constipation and the relative mechanisms based on the protein digestion and absorption pathway. J Transl Med. 2021;19:490.PubMedCentralPubMed
23.
go back to reference Aziz I, Whitehead WE, Palsson OS, Törnblom H, Simrén M. An approach to the diagnosis and management of Rome IV functional disorders of chronic constipation. Expert Rev Gastroenterol Hepatol. 2020;14:39–46.PubMed Aziz I, Whitehead WE, Palsson OS, Törnblom H, Simrén M. An approach to the diagnosis and management of Rome IV functional disorders of chronic constipation. Expert Rev Gastroenterol Hepatol. 2020;14:39–46.PubMed
24.
go back to reference Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32:920–4.PubMed Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32:920–4.PubMed
25.
go back to reference Agachan F, Chen T, Pfeifer J, Reissman P, Wexner SD. A constipation scoring system to simplify evaluation and management of constipated patients. Dis Colon Rectum. 1996;39:681–5.PubMed Agachan F, Chen T, Pfeifer J, Reissman P, Wexner SD. A constipation scoring system to simplify evaluation and management of constipated patients. Dis Colon Rectum. 1996;39:681–5.PubMed
26.
go back to reference Peng Z, Xiang J, He Z, Zhang T, Xu L, Cui B, et al. Colonic transendoscopic enteral tubing: a novel way of transplanting fecal microbiota. Endosc Int Open. 2016;4:E610–3.PubMedCentralPubMed Peng Z, Xiang J, He Z, Zhang T, Xu L, Cui B, et al. Colonic transendoscopic enteral tubing: a novel way of transplanting fecal microbiota. Endosc Int Open. 2016;4:E610–3.PubMedCentralPubMed
27.
go back to reference Long C, Yu Y, Cui B, Jagessar SAR, Zhang J, Ji G, et al. A novel quick transendoscopic enteral tubing in mid-gut: technique and training with video. BMC Gastroenterol. 2018;18:37.PubMedCentralPubMed Long C, Yu Y, Cui B, Jagessar SAR, Zhang J, Ji G, et al. A novel quick transendoscopic enteral tubing in mid-gut: technique and training with video. BMC Gastroenterol. 2018;18:37.PubMedCentralPubMed
28.
go back to reference National Institutes of Health and National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017. National Institutes of Health and National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017.
29.
go back to reference Pannemans J, Masuy I, Tack J. Functional constipation: Individualising Assessment and Treatment. Drugs. 2020;80:947–63.PubMed Pannemans J, Masuy I, Tack J. Functional constipation: Individualising Assessment and Treatment. Drugs. 2020;80:947–63.PubMed
30.
go back to reference Schiller LR. Chronic constipation: new insights, better outcomes? Lancet Gastroenterol Hepatol. 2019;4:873–82.PubMed Schiller LR. Chronic constipation: new insights, better outcomes? Lancet Gastroenterol Hepatol. 2019;4:873–82.PubMed
31.
go back to reference Törnblom H, Van Oudenhove L, Sadik R, Abrahamsson H, Tack J, Simrén M. Colonic transit time and IBS symptoms: what’s the link? Am J Gastroenterol. 2012;107:754–60.PubMed Törnblom H, Van Oudenhove L, Sadik R, Abrahamsson H, Tack J, Simrén M. Colonic transit time and IBS symptoms: what’s the link? Am J Gastroenterol. 2012;107:754–60.PubMed
32.
go back to reference Glia A, Lindberg G, Nilsson LH, Mihocsa L, Akerlund JE. Clinical value of symptom assessment in patients with constipation. Dis Colon Rectum. 1999;42:1401–8. discussion 8–10.PubMed Glia A, Lindberg G, Nilsson LH, Mihocsa L, Akerlund JE. Clinical value of symptom assessment in patients with constipation. Dis Colon Rectum. 1999;42:1401–8. discussion 8–10.PubMed
33.
go back to reference Vandeputte D, Falony G, Vieira-Silva S, Tito RY, Joossens M, Raes J. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut. 2016;65:57–62.PubMed Vandeputte D, Falony G, Vieira-Silva S, Tito RY, Joossens M, Raes J. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut. 2016;65:57–62.PubMed
34.
go back to reference Vork L, Penders J, Jalanka J, Bojic S, van Kuijk SMJ, Salonen A, et al. Does Day-to-day variability in Stool consistency link to the fecal microbiota composition? Front Cell Infect Microbiol. 2021;11:639667.PubMedCentralPubMed Vork L, Penders J, Jalanka J, Bojic S, van Kuijk SMJ, Salonen A, et al. Does Day-to-day variability in Stool consistency link to the fecal microbiota composition? Front Cell Infect Microbiol. 2021;11:639667.PubMedCentralPubMed
35.
go back to reference Tigchelaar EF, Bonder MJ, Jankipersadsing SA, Fu J, Wijmenga C, Zhernakova A. Gut microbiota composition associated with stool consistency. Gut. 2016;65:540–2. Tigchelaar EF, Bonder MJ, Jankipersadsing SA, Fu J, Wijmenga C, Zhernakova A. Gut microbiota composition associated with stool consistency. Gut. 2016;65:540–2.
36.
go back to reference Kwon HJ, Lim JH, Kang D, Lim S, Park SJ, Kim JH. Is stool frequency associated with the richness and community composition of gut microbiota? Intest Res. 2019;17:419–26.PubMedCentral Kwon HJ, Lim JH, Kang D, Lim S, Park SJ, Kim JH. Is stool frequency associated with the richness and community composition of gut microbiota? Intest Res. 2019;17:419–26.PubMedCentral
37.
go back to reference Turpin W, Kelly O, Borowski K, Boland K, Tyler A, Cohen Z, et al. Mucosa-Associated Microbiota in Ileoanal Pouches May contribute to clinical symptoms, particularly Stool frequency, Independent of Endoscopic Disease Activity. Clin Transl Gastroenterol. 2019;10:1–7.PubMed Turpin W, Kelly O, Borowski K, Boland K, Tyler A, Cohen Z, et al. Mucosa-Associated Microbiota in Ileoanal Pouches May contribute to clinical symptoms, particularly Stool frequency, Independent of Endoscopic Disease Activity. Clin Transl Gastroenterol. 2019;10:1–7.PubMed
38.
go back to reference Martin-Gallausiaux C, Marinelli L, Blottière HM, Larraufie P, Lapaque N. SCFA: mechanisms and functional importance in the gut. Proc Nutr Soc. 2021;80:37–49.PubMed Martin-Gallausiaux C, Marinelli L, Blottière HM, Larraufie P, Lapaque N. SCFA: mechanisms and functional importance in the gut. Proc Nutr Soc. 2021;80:37–49.PubMed
39.
go back to reference Cıralı C, Ulusoy E, Kume T, Arslan N. Elevated serum neopterin levels in children with functional constipation: association with systemic proinflammatory cytokines. World J Pediatr. 2018;14:448–53.PubMed Cıralı C, Ulusoy E, Kume T, Arslan N. Elevated serum neopterin levels in children with functional constipation: association with systemic proinflammatory cytokines. World J Pediatr. 2018;14:448–53.PubMed
40.
go back to reference Mokhtare M, Alimoradzadeh R, Agah S, Mirmiranpour H, Khodabandehloo N. The Association between modulating inflammatory cytokines and constipation of Geriatrics in Iran. Middle East J Dig Dis. 2017;9:228–34.PubMedCentralPubMed Mokhtare M, Alimoradzadeh R, Agah S, Mirmiranpour H, Khodabandehloo N. The Association between modulating inflammatory cytokines and constipation of Geriatrics in Iran. Middle East J Dig Dis. 2017;9:228–34.PubMedCentralPubMed
41.
go back to reference Krogh K, Chiarioni G, Whitehead W. Management of chronic constipation in adults. United Eur Gastroenterol J. 2017;5:465–72. Krogh K, Chiarioni G, Whitehead W. Management of chronic constipation in adults. United Eur Gastroenterol J. 2017;5:465–72.
42.
go back to reference Yang B, Tian H, Ye C, Lin Z, Zhao D, Ma C, et al. The efficacy and safety of fecal microbiota transplantation combined with biofeedback for mixed constipation: a retrospective cohort study. Front Med (Lausanne). 2021;8:746990.PubMed Yang B, Tian H, Ye C, Lin Z, Zhao D, Ma C, et al. The efficacy and safety of fecal microbiota transplantation combined with biofeedback for mixed constipation: a retrospective cohort study. Front Med (Lausanne). 2021;8:746990.PubMed
43.
go back to reference Zhang F, Cui B, He X, Nie Y, Wu K, Fan D. Microbiota transplantation: concept, methodology and strategy for its modernization. Protein Cell. 2018;9:462–73.PubMedCentralPubMed Zhang F, Cui B, He X, Nie Y, Wu K, Fan D. Microbiota transplantation: concept, methodology and strategy for its modernization. Protein Cell. 2018;9:462–73.PubMedCentralPubMed
44.
go back to reference Kao D, Roach B, Silva M, Beck P, Rioux K, Kaplan GG, et al. Effect of oral Capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a Randomized Clinical Trial. JAMA. 2017;318:1985–93.PubMedCentralPubMed Kao D, Roach B, Silva M, Beck P, Rioux K, Kaplan GG, et al. Effect of oral Capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a Randomized Clinical Trial. JAMA. 2017;318:1985–93.PubMedCentralPubMed
45.
go back to reference Youngster I, Sauk J, Pindar C, Wilson RG, Kaplan JL, Smith MB, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis. 2014;58:1515–22.PubMedCentralPubMed Youngster I, Sauk J, Pindar C, Wilson RG, Kaplan JL, Smith MB, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis. 2014;58:1515–22.PubMedCentralPubMed
46.
go back to reference Fang S, Wu S, Ji L, Fan Y, Wang X, Yang K. The combined therapy of fecal microbiota transplantation and laxatives for functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Med (Baltim). 2021;100:e25390. Fang S, Wu S, Ji L, Fan Y, Wang X, Yang K. The combined therapy of fecal microbiota transplantation and laxatives for functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Med (Baltim). 2021;100:e25390.
47.
go back to reference El-Salhy M, Hausken T, Hatlebakk JG. Increasing the dose and/or repeating faecal microbiota transplantation (FMT) increases the response in patients with irritable bowel syndrome (IBS). Nutrients. 2019;11. El-Salhy M, Hausken T, Hatlebakk JG. Increasing the dose and/or repeating faecal microbiota transplantation (FMT) increases the response in patients with irritable bowel syndrome (IBS). Nutrients. 2019;11.
48.
go back to reference Lee CH, Belanger JE, Kassam Z, Smieja M, Higgins D, Broukhanski G, et al. The outcome and long-term follow-up of 94 patients with recurrent and refractory Clostridium difficile infection using single to multiple fecal microbiota transplantation via retention enema. Eur J Clin Microbiol Infect Dis. 2014;33:1425–8.PubMed Lee CH, Belanger JE, Kassam Z, Smieja M, Higgins D, Broukhanski G, et al. The outcome and long-term follow-up of 94 patients with recurrent and refractory Clostridium difficile infection using single to multiple fecal microbiota transplantation via retention enema. Eur J Clin Microbiol Infect Dis. 2014;33:1425–8.PubMed
49.
go back to reference Baunwall SMD, Lee MM, Eriksen MK, Mullish BH, Marchesi JR, Dahlerup JF et al. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: an updated systematic review and meta-analysis. EClinicalMedicine. 2020;29–30:100642. Baunwall SMD, Lee MM, Eriksen MK, Mullish BH, Marchesi JR, Dahlerup JF et al. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: an updated systematic review and meta-analysis. EClinicalMedicine. 2020;29–30:100642.
50.
go back to reference Mocanu V, Rajaruban S, Dang J, Kung JY, Deehan EC, Madsen KL. Repeated fecal Microbial Transplantations and Antibiotic Pre-Treatment are linked to Improved Clinical Response and Remission in Inflammatory Bowel Disease: a systematic review and pooled proportion Meta-analysis. J Clin Med. 2021;10. Mocanu V, Rajaruban S, Dang J, Kung JY, Deehan EC, Madsen KL. Repeated fecal Microbial Transplantations and Antibiotic Pre-Treatment are linked to Improved Clinical Response and Remission in Inflammatory Bowel Disease: a systematic review and pooled proportion Meta-analysis. J Clin Med. 2021;10.
51.
go back to reference Ge X, Tian H, Ding C, Gu L, Wei Y, Gong J, et al. Fecal microbiota transplantation in combination with Soluble Dietary Fiber for treatment of slow transit constipation: a pilot study. Arch Med Res. 2016;47:236–42.PubMed Ge X, Tian H, Ding C, Gu L, Wei Y, Gong J, et al. Fecal microbiota transplantation in combination with Soluble Dietary Fiber for treatment of slow transit constipation: a pilot study. Arch Med Res. 2016;47:236–42.PubMed
52.
go back to reference Kluzek S, Dean B, Wartolowska KA. Patient-reported outcome measures (PROMs) as proof of treatment efficacy. BMJ Evid Based Med. 2022;27:153–5.PubMed Kluzek S, Dean B, Wartolowska KA. Patient-reported outcome measures (PROMs) as proof of treatment efficacy. BMJ Evid Based Med. 2022;27:153–5.PubMed
Metadata
Title
Efficacy of washed microbiota transplantation for therapeutic targets of refractory functional constipation and the influencing factors: a single-center, retrospective, 24-week follow-up study
Authors
Liquan Wu
Qingfen Yuan
Lihao Wu
Harry Hua-Xiang Xia
Muxiao Zhong
Tao Liu
Xiaoyan Ye
Danping Luo
Jiating Xu
Wenrui Xie
Xingxiang He
Jieyi Cai
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-02929-7

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.